Exoskeleton maker MileBot raises nearly 100M CNY from CSC Financial
What's the deal? MileBot Robotics, a Chinese medical exoskeleton company, has raised nearly 100 million CNY (about $14.9 million) in a strategic late-stage round from CSC FinancialDealroom has a profile for this one. Try Dealroom → (China SecuritiesDealroom has a profile for this one. Try Dealroom →). Haoguan CapitalDealroom has a profile for this one. Try Dealroom → acted as sole financial adviser.
What does MileBot do? The company builds exoskeletons for rehabilitation, using a self-developed flexible actuator that supports active — rather than passive — training for patients recovering from strokes and spinal-cord injuries. Its products span in-hospital rehab, home care, and daily mobility, and its core devices carry NMPA Class II medical-device certification.
By the numbers: MileBot says revenue grew nearly 200% in 2025, with overseas markets contributing more than a third. Founder Chen Gong, who holds a biomedical engineering doctorate from the National University of Singapore, frames the product as "an intelligent partner that can understand a patient's intentions" (translated from Chinese).
The new hire: The company has appointed Chen Kangning as chief executive officer. She previously held senior roles at Johnson & JohnsonDealroom has a profile for this one. Try Dealroom → and other multinational medical firms, bringing experience across product registration, compliance, and distribution. The hire marks a shift from a product-centred model to a clinically focused commercial system.
What's the endgame? Following its Series B, MileBot is pushing product iteration and frontier work in brain-computer interfaces (BCIs), pairing them with its exoskeletons so patients can "drive the body with thought." It aims to cover the "last mile" of care across hospitals, communities, and homes.
Why now? China's National Healthcare Security Administration set up pricing categories for invasive and non-invasive BCIs in 2025, while the technology was still in the lab. On March 22, 2026, the world's first invasive BCI medical device was approved and assigned an insurance code — opening a reimbursement path MileBot hopes to follow.
The signal: MileBot holds more than 200 patents and sells into hundreds of Chinese hospitals, giving it a medical-grade base as exoskeletons move from novelty to everyday clinical tools. Its bet is that early profitability and deep technical work can coexist in medical rehabilitation — and that the same route can carry BCIs from the lab to the bedside.
Image credit: Generated with Gemini
